Picture [LSA] – The Business Web Portal 650x89px
All >

News > Southern Europe & Israel

Please find below news about Albania, Bosnia and Herzegovina, Croatia, Greece, Israel, Italy, Malta, Montenegro, Portugal, Macedonia, Serbia, Slovenia, Spain and Turkey as well as about organisations from these countries.

Total search results: 735 | Ordered by Source (descending)
1 2 3 4 5 6 7 8  next pagenext page

order ascendingorder descendingSource order ascendingorder descendingDate
[iito] Business Intelligence. (10/31/18). "Press Release: [iito] Discontinues All Data Will Still Be Available at". Bremen. 2018-10-31
Zivak Technologies. (10/3/13). "Press Release: Introduction of SPE9600 Automated 96-Well-Plate SPE System at Medica 2013 Fair". 2013-10-03
Zivak Technologies. (10/2/13). "Press Release: ZinMass Clinical LC-MS/MS Analyzer Will Be Exhibited at Medica 2013". 2013-10-02
Zeltia S.A.. (9/15/15). "Press Release: PharmaMar Opens New Affiliate in UK". Madrid. 2015-09-15
Zeltia S.A.. (9/1/15). "Press Release: Pharmaceutical Council Recommends Approval of Yondelis (trabectedin) in Japan". Madrid. 2015-09-01
Zeltia S.A.. (8/20/15). "Press Release: PharmaMar Announces License Agreement with Specialised Therapeutics Australia Pty for Aplidin (plitidepsin) in Oncology". Madrid. 2015-08-20
Zeltia S.A.. (7/31/15). "Press Release: PharmaMar Passes the U.S. FDA Manufacturing Inspection for Yondelis Active Ingredient". Madrid. 2015-07-31
Zeltia S.A.. (7/28/15). "Press Release: Grupo Zeltia Reports First Half 2015 Financial Results". Madrid. 2015-07-28
Zeltia S.A.. (7/23/15). "Press Release: PharmaMar Announces License Agreement with TTY Biopharm for Aplidin (plitidepsin) in Hematological Cancers". Madrid. 2015-07-23
Zeltia S.A.. (7/23/14). "Press Release: PharmaMar Initiates a Phase I Study with Aplidin in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma". Madrid. 2014-07-23
Zeltia S.A.. (7/23/12). "Press Release: Report at 30 June 2012. 1H12 Highlights". Madrid. 2012-07-23
Zeltia S.A.. (7/22/15). "Press Release: Genomica and the Foundation for Excellence and Quality in Oncology Announce a Framework Agreement for Collaboration in Oncology". Madrid. 2015-07-22
Zeltia S.A.. (7/2/12). "Press Release: Zeltia Announces that Subsidiary PharmaMar Is Commencing a Phase II Trial with PM01183 in Patients with Breast Cancer". Madrid. 2012-07-02
Zeltia S.A.. (7/17/14). "Press Release: Sylentis Receives Authorisation to Commence Phase IIb Clinical Trial with Bamosiran (SYL040012) for Treating Ocular Hypertension Associated with Glaucoma". Madrid. 2014-07-17
Zeltia S.A.. (6/29/15). "Press Release: PharmaMar Initiates the Phase III Study CORAIL for the Anticancer Agent PM1183 in Patients with Platinum-resistant Ovarian Cancer". Madrid. 2015-06-29
Zeltia S.A.. (6/29/12). "Press Release: Zeltia Receives 9.5 Million Euro from the Spanish Public Administrations for the Payment of Outstanding Invoices". Madrid. 2012-06-29
Zeltia S.A.. (2/3/15). "Press Release: U.S. FDA Grants Priority Review to Yondelis NDA for Advanced Soft-tissue Sarcoma". Madrid. 2015-02-03
Zeltia S.A.. (2/28/14). "Press Release: Zeltia Net Profit Soars 72%. Reported EBITDA of 23.8 Million Euros Increased by 16.6%". Madrid. 2014-02-28
Zeltia S.A.. (2/28/13). "Press Release: Zeltia Posts Net Attributable Profit of €6.6 Million (+39%)". Madrid. 2013-02-28
Zeltia S.A.. (2/27/13). "Press Release: Zeltia Announces that Subsidiary Sylentis Has Commenced Phase II Clinical Trials with Compound SYL1001 for Treating Eye Discomfort Associated with Dry Eye Syndrome". Madrid. 2013-02-27
Zeltia S.A.. (2/26/15). "Press Release: Zeltia's Board of Directors Will Propose to the Next Shareholders' Meeting that Pharma Mar Merge with and Absorb Its Parent Company, Zeltia. The Board of Directors Will also Request that Pharma Mar Seek an IPO in 2015-02-26
Zeltia S.A.. (2/26/15). "Press Release: Grupo Zeltia Net Attributable Profit Amounted to 13 Million Euro in 2014 (+16%). Group Total Revenues Amounted to 178 Million Euro (+8%).". Madrid. 2015-02-26
Zeltia S.A.. (12/2/14). "Press Release: Zeltia Announces that Its Board of Directors Has Approved a Strategy to Explore Merging PharmaMar and Zeltia in Advance of a Listing Request in the US". Madrid. 2014-12-02
Zeltia S.A.. (11/7/12). "Press Release: PharmaMar Germany Commences Commercial Activity". Madrid. 2012-11-07
Zeltia S.A.. (11/25/14). "Press Release: PharmaMar Announces that Its Partner Janssen Has Submitted a New Drug Application for Yondelis to the U.S. FDA for the Treatment of Advanced Soft Tissue Sarcoma". Madrid. 2014-11-25
Zeltia S.A.. (11/20/14). "Press Release: PharmaMar Results for Antitumoral Compounds and Their Mechanism of Action at EORTC-NCI-AACR Emphasize an Innovative Pipeline of Targeted Ttherapies". Barcelona. 2014-11-20
Zeltia S.A.. (10/25/12). "Press Release: Zeltia Group Operating Revenues up 7%". Madrid. 2012-10-25
Zeltia S.A.. (1/22/13). "Press Release: Genomica AB Starts Its Commercial Activity". Madrid. 2013-01-22
Zeltia S.A.. (1/13/15). "Press Release: PharmaMar Will Start a Phase III Study of PM1183 in Combination with Doxorubicin in Relapsed SCLC". Madrid. 2015-01-13
Zambon Group. (7/25/19). "Press Release: Zambon Completes Transformational Acquisition of Breath Therapeutics". Milan. 2019-07-25
Zambon Group. (6/19/14). "Press Release: Zambon Italy and Mundipharma Signed a Co-Marketing and Distribution Agreement". 2014-06-19
Ysios Capital. (9/24/18). "Press Release: Ysios Capital Strengthens Its Team with the Appointment of Guillem Laporta as Principal and Two New Venture Partners". Barcelona. 2018-09-24
Ysios Capital. (3/19/14). "Press Release: Ysios Capital Begins Fundraising for Ysios Biofund II. New Fund to Back Disruptive Life Sciences Company in Europe and US". Barcelona. 2014-03-19
Ysios Capital. (10/18/16). "Press Release: Ysios Capital Raises €126,4 m ($140 m) for Its Second Fund, Ysios Biofund II Innvierte". Barcelona. 2016-10-18
Ysios Capital Partners. (12/01/2011). "Press Release: Ysios Capital Partners and “la Caixa” Lead MedLumics €3.5million/$4.7million Series A Financing". Madrid. 2011-12-01
Ysios Capital Partners. (09/21/2010). "Press Release: Ysios Capital Partners Leads €5 Million Series A Financing of Sabirmedical". Barcelona. 2010-09-21
Ysios Capital Partners. (09/13/2011). "Press Release: Ysios Capital Partners Leads €29.2million Series D Financing of AM-Pharma". Barcelona. 2011-09-13
Ysios Capital Partners. (05/29/2012). "Press Release: Cristina Garmendia Returns to Ysios Capital as Partner". Barcelona. 2012-05-29
Xeltis AG. (11/15/17). "Press Release: Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs". Zurich & Eindhoven. 2017-11-15
Wise S.r.l.. (5/25/17). "Press Release: Wise Srl Raises EUR 6.5 Million for Clinical Validation of Novel Neuroelectrodes for Brain Monitoring and Spinal Cord Stimulation". Milan & Berlin. 2017-05-25
Wilex AG. (11/21/11). "Press Release: Wilex AG. ARISER Independent Data Monitoring Committee (IDMC) Recommends Conducting the Final Analysis of the Pivotal Phase III Trial with Rencarex". Munich. 2011-11-21
Waters Corporation. (3/14/13). "Press Release: Waters and DANI Instruments Announce Integrated and Compatible Network. Waters Empower Software Now Works Seamlessly with DANI Headspace and GC Instruments". Milford, MA. 2013-03-14
VWR International, LLC. (9/2/11). "Press Release: VWR International, LLC Acquires International P.B.I. S.p.A. – VWR Strengthens Its Position in Italy". Radnor, PA. 2011-09-02
VUV Analytics, Inc.. (6/7/16). "Press Release: VUV Analytics Launches Next Generation Gas Chromatography Detector. VGA-101 Presents the Latest Innovation in Vacuum Ultraviolet Spectroscopy". Austin, TX. 2016-06-07
Vernalis plc. (8/24/11). "Press Release: Vernalis Initiates Phase I Trial of V81444 for Parkinson’s Disease". 2011-08-24
Vermillion, Inc.. (8/3/11). "Press Release: Vermillion Appoints Distribution Partner for OVA1 in Israel and the Palestine Territories". Austin, TX. 2011-08-03
VCN Biosciences SL. (7/9/12). "Press Release: Grifols Acquires 40% of the Capital of Biotechnology Firm VCN Bioscience. The Group’s Investment Will Ensure the Viability of Research Projects in the Field of Oncology". Barcelona. 2012-07-09
Valneva S.E.. (8/27/15). "Press Release: Valneva Announces Two New EB66 Agreements. 7 new EB66 Deals Signed Since the Beginning of the Year". Lyon. 2015-08-27
Valneva S.E.. (6/22/15). "Press Release: Valneva Takes Direct Control Over Marketing and Distribution of Ixiaro to Increase Margin and Profitability ". Lyon. 2015-06-22
Vall d’Hebron Institute of Oncology (VHIO). (6/10/15). "Press Release: Vall d’Hebron Institute of Oncology and AstraZeneca Form an Oncology Alliance". 2015-06-10
Universität Stuttgart. (12/10/12). "Pressemitteilung: Uni Stuttgart und Oncomatrix starten Forschungskooperation. Neue Krebsmedikamente für die Behandlung metastasierender Tumore". 2012-12-10
Uniqure N.V.. (7/31/17). "Press Relase: Uniqure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B". Lexington, MA & Amsterdam. 2017-07-31
Uniqure N.V.. (6/6/14). "Press Release: uniQure Announces Results for the First Quarter 2014". Amsterdam. 2014-06-06
Uniqure N.V.. (4/26/17). "Press Release: Uniqure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at CHDI’s 12th Annual Huntington's Disease Therapeutics Conference". Lexington, MA & Amsterdam. 2017-04-26
Uniqure N.V.. (4/20/17). "Press Release: Uniqure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in Europe". Lexington, MA & Amsterdam. 2017-04-20
Uniqure N.V.. (12/1/14). "Press Release: Uniqure Announces Results for the Third Quarter of 2014". Amsterdam. 2014-12-01
Uniqure N.V.. (10/19/17). "Press Release: Uniqure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX (FIX-Padua)". Lexington, MA & Amsterdam. 2017-10-19
Uniqure B.V.. (7/9/13). "Press Release: Uniqure Signs EU Commercialization Agreement with Chiesi Farmaceutici for First Approved Gene Therapy Treatment, and Announces EUR 45 Million (USD 58 Million) in Equity and Collaboration Financing". Amsterdam. 2013-07-09
TÜV Süd AG. (1/11/13). "Press Release: TÜV Süd Acquires Food Laboratory in Italy". 2013-01-11
TxCell S.A.. (4/25/16). "Press Release: TxCell and Ospedale San Raffaele Launch Collaboration for the Development of CAR-Tregs in Lupus Nephritis". Valbonne & Milan. 2016-04-25
TxCell S.A.. (4/25/16). "Press Release: Letter to Shareholders – from Stéphane Boissel, CEO of TxCell April 25, 2016". Valbonne & Milan. 2016-04-25
Transgene S.A.. (4/24/17). "Press Release: SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer". Seoul, San Francisco, CA & Strasbourg. 2017-04-24
TiGenix N.V.. (8/23/12). "Press Release: TiGenix Financial Half-year Results 2012". 2012-08-23
TiGenix N.V.. (7/30/15). "Press Release: TiGenix Expands Pipeline and Enters the Cardiology Field with Clinical-stage Company Acquisition". Leuven. 2015-07-30
TiGenix N.V.. (2/25/11). "Press Release: TiGenix Announces Proposed Combination with Cellerix. Presentation – Creating the European Cell Therapy Leader". Leuven & Tres Cantos. 2011-02-25
TiGenix N.V.. (2/25/11). "Press Release: TiGenix Announces Proposed Combination with Cellerix and Capital Increase through a Public Rights Offering. Combination Will Create the European Cell Therapy Leader with Two Marketed Products and a Promising Pipel 2011-02-25
TiGenix N.V.. (11/22/13). "Press Release: TiGenix Completes EUR 12 Million Capital Increase with Strategic Investor Grifols". Leuven. 2013-11-22
Thermo Fisher Scientific Inc.. (9/3/14). "Press Release: Thermo Fisher Scientific Teams with National Reference Labs on New European Regulation, Allowing GC-MS/MS to Confirm Dioxins in Feed and Food". 2014-09-03
Thermo Fisher Scientific Inc.. (8/27/18). "Press Release: Differential Ion Mobility Interface Boosts Proteomics Workflow Performance". Florence. 2018-08-27
Thermo Fisher Scientific Inc.. (7/22/10). "Press Release: Thermo Fisher Scientific Announces Implementation of GC/MS and LC/MS Intstrumentation for Rapid and Reliable Pesticide Analysis in Food at Conserve Italia". Austin, TX. 2010-07-22
Thermo Fisher Scientific Inc.. (6/12/17). "Press Release: Thermo Fisher Scientific Ushers in New Era of Clinical Mass Spectrometry with World's First Fully Integrated Laboratory Analyzer". Athens. 2017-06-12
Thermo Fisher Scientific Inc.. (12/15/15). "Press Release: Thermo Fisher Scientific Awards 2015 Attune NxT Flow Cytometry Grant to California Cancer Researcher". Albany, NY. 2015-12-15
Thermo Fisher Scientific Inc.. (11/19/13). "Press Release: Leading EU and UK Pesticide Testing Labs Collaborate with Thermo Fisher Scientific". Runcorn. 2013-11-19
Thermo Fisher Scientific Inc.. (10/17/13). "Press Release: European Institute of Oncology Implements Thermo Scientific LIMS for Biobanks". Philadeliphia, PA. 2013-10-17
TFS Trial Form Support International AB. (12/5/12). "Press Release: TFS International Acquires All Shares of Dimensione Ricerca". Lund. 2012-12-05
Telormedix S.A.. (1/31/12). "Press Release: Telormedix Elected Member of TIMER Collaborative Research Programme. EU and Brazil Invest in TIMER Research Collaboration to Fight Inflammtory Disorders". Bioggio, TI. 2012-01-31
Tecan Group Ltd.. (6/23/17). "Press Release: DiaSorin and Tecan to Collaborate in New Platform Development". Saluggia & Männedorf. 2017-06-23
Tecan Group Ltd.. (10/22/13). "Press Release: Enhancing Clinical Diagnostics with Tecan’s Cavro OmniRobot". Männedorf. 2013-10-22
Tecan Group Ltd.. (1/12/11). "Press Release: Tecan Announces OEM Agreement with DiaSorin. Tecan to Supply Fully Automated Clinical ELISA Platform and Various Detection Instruments for MUREX Product Line". Männedorf. 2011-01-12
Takeda Pharmaceutical Co. Ltd.. (2/24/15). "Press Release: Takeda to Acquire Select Portfolio from Neutec, Significantly Enhancing its Business in Turkey". Osaka & Istanbul. 2015-02-24
T.B.N. Group, The. (1/12/12). "Press Release: BioInvest Israel 2012. Local & Global Pharma, Medtech and Finance Companies Meet to Talk Business". Haifa. 2012-01-12
Sysmex Corporation. (1/21/14). "Press Release: Sysmex Reinforces Sales and Support Structure in Turkey. Establishes Local Subsidiary to Expand Business in Growing Market". 2014-01-21
Symrise AG. (5/6/19). "Press Release: Symrise Acquires Italian Biotech Company Cutech. Adds Competitive Edge in Bio-analytical Methods – Expands R&D Capacities for the Efficacy Testing of Cosmetic Ingredients". 2019-05-06
Symphogen A/S. (3/7/11). "Press Release: Symphogen Receives US Patent on Lead Cancer Compound Sym004. Sym004 Anti-cancer Activity Highlighted at Major Oncology Meeting". Paris. 2011-03-07
Sygnis Pharma AG. (8/14/12). "Press Release: Sygnis Announces Three Months Results for Fiscal Year 2012/2013". Heidelberg. 2012-08-14
Sygnis Pharma AG. (7/25/12). "Press Release: Sygnis Reports Financial Results for Fiscal Year 2011/12. Strategic Realignment Successfully Initiated". Heidelberg. 2012-07-25
Sygnis Pharma AG. (7/18/12). "Press Release: Sygnis and Genetrix Announce Proposed Combination of Businesses of Sygnis and Genetrix’ Subsidiary X-Pol". Heidelberg. 2012-07-18
Sygnis Pharma AG. (4/30/13). "Press Release: Sygnis Reports Financial Results for Fiscal Year 2012". Heidelberg. 2013-04-30
Sygnis Pharma AG. (3/25/13). "Press Release: Sygnis Announces Management Board Changes (Ad hoc-Release)". Heidelberg & Madrid. 2013-03-25
Sygnis Pharma AG. (12/6/12). "Press Release: Sygnis Announces Completion of the X-Pol Biotech Acquisition. Registration of the Transaction and the Previous Capital Reduction (Ratio 8:1) in the Commercial Register". Heidelberg. 2012-12-06
Sygnis Pharma AG. (12/20/12). "Press Release: Sygnis Announces the Adaptation of Its Organisation to the New Business Activity". Heidelberg. 2012-12-20
Sygnis Pharma AG. (11/14/12). "Press Release: Sygnis Announces Six Months Results of Fiscal Year 2012". Heidelberg. 2012-11-14
Sygnis Pharma AG. (10/18/12). "Press Release: Annual General Meeting of Sygnis Pharma AG Approves Combination of Businesses with X-Pol Biotech. Comprehensive Strategic Realignment Agreed – Election of New Supervisory Board". Heidelberg. 2012-10-18
Sygnis AG. (5/13/15). "Press Release: Sygnis AG Announces Genetrix S.L. Has Taken Over All Shares from Genetrix Life Sciences AB to Become New Majority Shareholder". Madrid & Heidelberg. 2015-05-13
Sygnis AG. (11/17/15). "Press Release: Sygnis AG Plans to Issue New Shares to Finance further Growth and Commercialization of Proprietary Product Portfolio [Not for US, CA, JP and AU] NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN USA, CANADA, 2015-11-17
Sygnis AG. (10/27/16). "Press Release: Sygnis AG to Receive €1.9 Million Non-dilutive R&D Funding from the Spanish Government". Madrid & Heidelberg. 2016-10-27
Sygnis AG. (01/21/15). "Press Release: Sygnis Signs Distribution Agreement with BioNova Cientifica, for its Innovative TruePrime Single Cell WGA Kit in Spain". Madrid. 2015-01-21
Swedish Orphan Biovitrum AB. (5/3/17). "Press Release: Sobi Opens Office in Greece". 2017-05-03
STAT-Diagnostica & Innovation S.L.. (5/6/13). "Press Release: Medical Diagnostics Company STAT-Diagnostica Secures 22.1 Million USD / 17 Million Euros in Series B Financing". Barcelona. 2013-05-06
STAT-Diagnostica & Innovation S.L.. (4/11/16). "Press Release: STAT-Diagnostica Announces 25 Million Euros in Series C Financing Led by Gilde Healthcare. Funding Will Be Used to Accelerate Go-to-Market Strategy". Barcelona. 2016-04-11
1 2 3 4 5 6 7 8  next pagenext page


Picture [LSA] – The Business Web Portal 650x89px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px

» top